双转录因子染色垂体腺瘤的临床意义:27例病例系列
该回顾性多机构病例系列分析了2008至2021年间手术切除的27例病理确诊为双转录因子染色垂体腺瘤患者,其中85.2%为功能性腺瘤,以肢端肥大症最常见(86.4%),PIT-1/SF-1组合占85.2%,功能性腺瘤激素缓解率78%,平均随访28.5个月无复发或进展。
要点
- 双转录因子染色垂体腺瘤中85.2%为功能性腺瘤,肢端肥大症占86.4%。
- 最常见的转录因子组合为PIT-1/SF-1,占85.2%。
- 功能性双转录因子染色腺瘤激素缓解率78%,平均随访28.5个月无复发或进展。
核心结论
- 双转录因子染色垂体腺瘤是2021年世界卫生组织分类下一个小而具有临床相关性的诊断亚群,多数为生长激素分泌型。
- 使用转录因子染色进行精确分类对理解这些肿瘤的生物学行为起关键作用。
- 随着转录因子分类的演进,该亚群垂体腺瘤可获得良好的结局。
研究设计与样本
- 回顾性多机构数据库病历审查,纳入2008至2021年间手术切除的垂体腺瘤患者。
- 共27例病理确诊为双转录因子染色垂体腺瘤(表达2种以上转录因子免疫阳性)。
- 收集患者人口学、神经影像特征、组织病理学发现和临床数据。
主要发现
- 27例患者中女性17例(63%),年龄范围20至84岁。
- 23例(85.2%)为功能性垂体腺瘤,其中肢端肥大症为最常见的功能性亚型(86.4%)。
- 单个肿瘤中最常见的转录因子组合为PIT-1/SF-1(85.2%)。
- 6例垂体腺瘤Knosp海绵窦侵袭分级为3或4级;6例(24.0%)Ki-67标记指数≥3%,且均染色为PIT-1/SF-1。
- 功能性双转录因子染色垂体腺瘤中78%达到激素缓解;平均随访28.5个月期间无垂体腺瘤显示复发或进展证据。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: According to the 2017 World Health Organization classification of neuro-endocrine tumors, pituitary adenomas (PAs) are classified according to immunoexpression of the pituitary-specific transcription factors (TFs). A small subset of PAs exhibit multiple TF staining on immunohistochemistry and we present a series of 27 pathologically-confirmed cases of dual TF staining PAs (dsTF-PAs), and report clinically relevant implications. METHODS: A retrospective chart review of a multi-institutional database of patients with PAs surgically resected between 2008-2021 was performed. PAs expressing immunopositivity 2+ TFs. Patient demographics, neuro-imaging characteristics, histopathologic findings, and clinical data were collected. RESULTS: Twenty-seven patients had pathologically verified dsTF-PAs, of whom 17 were female (63%), with ages ranging from 20-84 years. Twenty-three (85.2%) patients harbored functional PAs, with acromegaly being the most common functional subtype (86.4%). The most common combination of TFs within a single tumor was PIT-1/SF-1 (85.2%). Six PAs exhibited Knosp cavernous sinus invasion grades of 3 or 4 and the Ki-67 labeling index was ≥3% in 6 patients (24.0%) and all stained for PIT-1/SF-1. Hormonal remission was achieved in 78% of functional dsTF-PAs. No PAs showed evidence of recurrence or progression over the mean follow-up period of 28.5 months. CONCLUSIONS: PAs exhibiting dsTF-PAs represent a small but clinically relevant diagnostic subset of PAs according to the 2021 World Health Organization criteria, as a majority are GH-producing. Precise classification using TF staining plays a key role in understanding the biology of these tumors. Favorable outcomes can be achieved in this subset of PAs with evolving TF classification.
引用
- Bove I, Cheok SK, Feng JJ, et al. Clinical Implications of Pituitary Adenomas Exhibiting Dual Transcription Factor Staining: A Case Series of 27 Patients. World Neurosurg. 2023. PMID: 37967742. doi:10.1016/j.wneu.2023.11.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。